In North America, rabies is rare — a few human cases per year. But the vaccine market is still strong, driven by animal bites (raccoons, bats, foxes) and pre‑travel vaccinations. The human rabies vaccine market analysis shows that North America holds 32% market share, with high prices per dose ($300‑$500). In contrast, Asia accounts for 95% of rabies deaths but only 25% of market value, because vaccines are cheaper ($10‑$50 per dose) and often subsidized.

India and China are the largest markets in Asia, but also the biggest tragedy: tens of thousands die yearly, mostly children, because they can't access timely PEP. The human rabies vaccine market forecast shows that the fastest growth will come from Asia, as Gavi and WHO fund mass vaccination campaigns. The challenge? Last‑mile distribution in rural areas, and convincing people that PEP works even if the bite happened days ago.

What works? Dog vaccination. If you vaccinate 70% of dogs, rabies transmission to humans plummets. That's why many experts say the human rabies vaccine market should shrink over time — not because of less human vaccine, but because we prevent the bites in the first place.

Until then, both markets will coexist: rich countries paying for convenience, poor countries fighting for survival.